Prostate cancer prostate carcinoma
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Retrospective cohort - Participants of Group 1 and/or 2 in PCMM. - Obtained informed consent in PCMM.;Prospective cohort - Men >= 18 years. - Planned to undergo prostate biopsies according to standard practice. - Signed informed consent.
Exclusion criteria
Exclusion criteria: Prospective cohort - Documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Predictive value of the novel genomic biomarker QUATTRO assessed in urine for detecting relevant cancer in a diagnostic prostate biopsy. - Predictive value of the novel genomic biomarkers QUATTRO assessed in urine and PPI assessed in a biopsy for detecting relevant cancer in a RP specimen. - Combined predictive value of the novel genomic biomarkers QUATTRO and PPI with MRI and histological biopsy markers for detecting relevant cancer in a RP specimen. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Modelled QUATTO and PPI data in decision support tools for prostate cancer. - Outcome on between-sites variability of the performance of the QUATTRO and PPI assays. | — |
Countries
Netherlands
Outcome results
None listed